The Jones Lab is interested in novel mechanisms of resistance to targeted therapies in acute myeloid leukemia (AML). AML is a cancer of the hematopoietic system and is characterized by abnormal proliferation of poorly differentiated cells that infiltrate the blood, bone marrow, and other tissues. While conventional chemotherapy is a mainstay of therapy, targeted therapies are being used in the treatment of AML more commonly. However, one limitation of targeted therapy is the existence of acquired or inherent resistance. The Jones Lab is interested in understanding the molecular underpinnings of these resistance mechanisms, as well as discovering novel therapeutic treatment modalities to overcome resistance.